Dr. Jiang Bin is an associate professor and postgraduate supervisor in the Department of Pharmaceutical Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University. She is also the Deputy Director of the Public Policy Research Center of Peking University, Vice Chairman of the Pharmaceutical Affairs Management Committee, Beijing Pharmaceutical Association, member of the Standing Committee of the Medical Insurance Professional Committee, China Association of Social Security. She was a senior visiting scholar at Harvard Medical School in 2010-2011.

Her research area includes: New medical reform and pharmaceutical industry development, decision-making and effect evaluation of drug policy, development and evaluation of drug supervision in China.

She has undertaken more than 20 research projects on medical reform and medical policies supported by national and regional governmental departments, industrial organizations and foundations related to medicine management, such as the National Healthcare Security Administration, the Medical Reform Office of the State Council, the National Development and Reform Commission, the National Health Commission (Ministry of Health), the Ministry of Science and Technology, China Food and Drug Administration (CFDA), the National Social Science Fund, RDPAC, CMB, Health Commission of Hebei Province and Guangdong Medical Price Association. She has published over 60 academic papers.

Her research topics include: “Research on the Monitoring and Evaluation of the Implementation of The Pilot Program of Centralized Procurement and Use of Drugs Organized by the State”, “Research on the Strategy and Policy of Boosting China's Pharmaceutical Industry through Innovation and Imitation Combined”, and “Influencing Factors and Intervention Study on Doctors’ Prescribing Behaviors based on the Selection of Generic and Original Branded Drug”, “Research on Drug Market Access System after Conformance Evaluation of the Quality and Efficacy of Generic Drugs”, “Research on the Progress and Impact of the Policy of Conformance Evaluation of Generic Drugs”, “Research on Disposal of Overdue Drugs in Chinese Households”, “Research on Quality Stratification System in Drug Bidding Purchases”, “Evaluation and Optimization of the Effect of Medicare Payment Price Policy for Medicines in China”, “Research on the Price Policy of Cheap drugs in shortage”, “White Paper on the status quo of Drug Safety Supervision in China”, “Research on the Performance Evaluation Index System of Drug Safety Supervision", “Research on the Operation of Institutions after Reforming the System of Supervision and Administration over Food and Drugs by Local Authorities”, “Development and Evaluation of Drug Supervision in China”, “Impact of GMP System on the Development of China's Pharmaceutical Industry”, “Research on Traceability Mechanism of the factory Price Information of Drugs”, “Study on the Rationality of the Resource Allocation for Food and Drug Supervision in China” and so on.